» Articles » PMID: 28155878

Immune Signature of Enhanced Functional Avidity CD8 T Cells in Vivo Induced by Vaccinia Vectored Vaccine

Overview
Journal Sci Rep
Specialty Science
Date 2017 Feb 4
PMID 28155878
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Functional avidity of T cells is a critical determinant for clearing viral infection and eliminating tumor. Understanding how functional avidity is maintained in T cells is imperative for immunotherapy. However, studies systematically characterize T cell with high functional avidity induced in vivo are still lacking. Previously, we and others found vaccinia vectored vaccine (VACV) induced antigen-specific CD8 T cells with relatively high functional avidity to those from DNA vaccine. Herein, we used functional, immune phenotyping and transcriptomic studies to define the immune signature of these CD8 T cells with high functional avidity. Antigen-specific CD8 T cells induced by VACV executed superior in vivo killing activity and displayed a distinct transcriptional profile, whereas no significantly differences were found in composition of memory sub-populations and cytokine poly-functionality. Transcriptional analyses revealed unique features of VACV induced CD8 T cells in several biological processes, including transport, cell cycle, cell communication and metabolic processes. In summary, we characterize CD8 T cells of high functional avidity induced in vivo by VACV, which not only improves our understanding of adaptive T cell immunity in VACV vaccination, but also provides clues to modulate functional avidity of CD8 T cells for T cell based immunotherapy.

Citing Articles

CD3 downregulation identifies high-avidity human CD8 T cells.

Clutton G, Weideman A, Mischell M, Kallon S, Conrad S, Shaw F Clin Exp Immunol. 2023; 215(3):279-290.

PMID: 37950348 PMC: 10876116. DOI: 10.1093/cei/uxad124.


Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects.

Shafer P, Kelly L, Hoyos V Front Immunol. 2022; 13:835762.

PMID: 35309357 PMC: 8928448. DOI: 10.3389/fimmu.2022.835762.


Biomechanics of T Cell Dysfunctions in Chronic Diseases.

Gunasinghe S, Peres N, Goyette J, Gaus K Front Immunol. 2021; 12:600829.

PMID: 33717081 PMC: 7948521. DOI: 10.3389/fimmu.2021.600829.


Constant regulation for stable CD8 T-cell functional avidity and its possible implications for cancer immunotherapy.

Gilfillan C, Hebeisen M, Rufer N, Speiser D Eur J Immunol. 2021; 51(6):1348-1360.

PMID: 33704770 PMC: 8252569. DOI: 10.1002/eji.202049016.


Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines.

Hu Z, Jiang W, Gu L, Qiao D, Shu T, Lowrie D J Mol Med (Berl). 2019; 97(12):1685-1694.

PMID: 31786669 DOI: 10.1007/s00109-019-01844-3.


References
1.
Wilde S, Sommermeyer D, Leisegang M, Frankenberger B, Mosetter B, Uckert W . Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition. J Immunol. 2012; 189(2):598-605. DOI: 10.4049/jimmunol.1102165. View

2.
Kroger C, Alexander-Miller M . Cutting edge: CD8+ T cell clones possess the potential to differentiate into both high- and low-avidity effector cells. J Immunol. 2007; 179(2):748-51. DOI: 10.4049/jimmunol.179.2.748. View

3.
Buggert M, Norstrom M, Salemi M, Hecht F, Karlsson A . Functional avidity and IL-2/perforin production is linked to the emergence of mutations within HLA-B*5701-restricted epitopes and HIV-1 disease progression. J Immunol. 2014; 192(10):4685-96. PMC: 4046013. DOI: 10.4049/jimmunol.1302253. View

4.
Vigano S, Utzschneider D, Perreau M, Pantaleo G, Zehn D, Harari A . Functional avidity: a measure to predict the efficacy of effector T cells?. Clin Dev Immunol. 2012; 2012:153863. PMC: 3511839. DOI: 10.1155/2012/153863. View

5.
Ercolini A, Ladle B, Manning E, Pfannenstiel L, Armstrong T, Machiels J . Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med. 2005; 201(10):1591-602. PMC: 2212915. DOI: 10.1084/jem.20042167. View